staa-8k_20200601.htm

0001564590-20-027750.txt : 20200601 0001564590-20-027750.hdr.sgml : 20200601 20200601090039 ACCESSION NUMBER: 0001564590-20-027750 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200601 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STAAR SURGICAL CO CENTRAL INDEX KEY: 0000718937 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 953797439 STATE OF INCORPORATION: DE FISCAL YEAR END: 0103 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11634 FILM NUMBER: 20931202 BUSINESS ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 6263037902 MAIL ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 FORMER COMPANY: FORMER CONFORMED NAME: STAAR SURGICAL COMPANY DATE OF NAME CHANGE: 19920703 8-K 1 staa-8k_20200601.htm 8-K staa-8k_20200601.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 1, 2020

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

Delaware	0-11634	95-3797439
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

25651 Atlantic Ocean Drive Lake Forest, California		92630
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



	Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 1, 2020, the Board of Directors of STAAR Surgical Company appointed Dr. Gilbert H. Kliman, 61, and Thomas G. Frinzi, 64, to serve as directors. The Board of Directors increased the size of the Board from five to six members. After these appointments and Mr. William Wall’s May 3, 2020 resignation, there are currently six members of the Board. Dr. Kliman and Mr. Frinzi will each receive the standard director compensation for a director, pro-rated for the remaining portion of the 2019-2020 term.

Dr. Kliman is a Managing Partner of InterWest Partners, a venture capital firm where he has been a partner since 1996. Dr. Kliman is a board-certified ophthalmologist and completed his residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He holds a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an MBA from the Stanford Graduate School of Business. Dr. Kliman has served on the board of directors of Glaukos Corporation almost continuously since 2007, was a lead investor and director of Avedro (acquired by Glaukos) and IntraLase (acquired by AMO), and currently serves as a director for ORBIS International and private healthcare companies.

Mr. Frinzi previously served as Worldwide President, Surgical, Johnson & Johnson Vision from February 2017 through December 2019. Mr. Frinzi was Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics (AMO) from January 2016 through February 2017 when Johnson & Johnson acquired AMO. Prior to joining AMO, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. He served as President and CEO of WaveTec Vision from 2010 through 2014. He has also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Chiron Vision. Mr. Frinzi earned a bachelor’s degree in political science from the University of Tampa

The Nominating and Governance Committee will assign committee memberships for Dr. Kliman and Mr. Frinzi after the 2020 Annual Meeting of Shareholders. The appointments of Dr. Kliman and Mr. Frinzi to the Board were not the result of any arrangement or understanding between Dr. Kliman or Mr. Frinzi and any other person or entity. There are no transactions between Dr. Kliman, nor Mr. Frinzi, nor any member of either of their immediate families, and the Company or any of its subsidiaries.

The information furnished herewith pursuant to Item 5.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 5.02 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.


	Item 9.01	Financial Statements and Exhibits


Exhibit No.	Description

99.1	Press release of the Company dated June 1, 2020.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


STAAR Surgical Company

June 1, 2020	By:	/s/ Caren Mason
		Caren Mason
		President and Chief Executive Officer

EX-99.1 2 staa-ex991_9.htm EX-99.1 staa-ex991_9.htm

Exhibit 99.1

Dr. Gil Kliman and Tom Frinzi Appointed to STAAR Surgical Board of Directors

LAKE FOREST, CA, June 1, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointment of Gilbert H. Kliman, M.D., Managing Partner, InterWest Partners and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its Board of Directors, effective June 1, 2020. The appointment of Messrs. Kliman and Frinzi brings the total number of members on STAAR's Board to six.

"The addition of Dr. Gil Kliman and Tom Frinzi to the STAAR Surgical Board of Directors adds extensive ophthalmology, commercial and medical device expertise to STAAR," said Lou Silverman, Chairman of the Board of STAAR Surgical. "Dr. Kliman is an investment professional and former practicing ophthalmologist who will bring a broad range of experiences and perspectives to STAAR’s Board. Tom’s leadership track record in ophthalmology and medical device spans more than 30 years and encompasses both large, well-established companies and innovative start-ups. We believe Gil and Tom’s familiarity with the opportunities and challenges faced by growth-oriented ophthalmic companies will provide valuable insight. On behalf of the entire Board, we look forward to Gil and Tom’s contributions to STAAR’s future successes.”

In addition to Dr. Kliman and Mr. Frinzi, STAAR will nominate its current directors, Stephen Farrell, Caren Mason, John Moore and Louis Silverman for election to serve as directors at its 2020 Annual Meeting of Shareholders scheduled for July 30, 2020.

About Gil Kliman

Gil Kliman, M.D., 61, is a Managing Partner of InterWest Partners, a venture capital firm where he has been a partner since 1996. Dr. Kliman is a board-certified ophthalmologist and completed his residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He holds a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an MBA from the Stanford Graduate School of Business. Dr. Kliman has served on the board of directors of Glaukos Corporation almost continuously since 2007, was a lead investor and director of Avedro (acquired by Glaukos) and IntraLase (acquired by AMO), and currently serves as a director for ORBIS International and private healthcare companies.

About Tom Frinzi

Tom Frinzi, 64, served as Worldwide President, Surgical, Johnson & Johnson Vision from February 2017 through December 2019. Mr. Frinzi was Senior Vice President of Abbott Laboratories and President of Abbott Medical Optics (AMO) from January 2016 through February 2017 when Johnson & Johnson acquired AMO. Prior to joining AMO, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. He served as President and CEO of WaveTec Vision from 2010 through 2014, when it was acquired by Alcon. He has also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Chiron Vision. Mr. Frinzi earned a B.A. in political science from the University of Tampa.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye, with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian^® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

CONTACT:Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

GRAPHIC 3 gze5ipfj4iwt000001.jpg GRAPHIC begin 644 gze5ipfj4iwt000001.jpg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end EX-101.SCH 4 staa-20200601.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 staa-20200601_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol(s) Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 6 staa-20200601_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 9 0001564590-20-027750-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-027750-xbrl.zip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end XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.staar.com/20200601/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports staa-8k_20200601.htm staa-20200601.xsd staa-20200601_lab.xml staa-20200601_pre.xml staa-ex991_9.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Jun. 01, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 01, 2020
Entity Registrant Name	STAAR Surgical Co
Entity Central Index Key	0000718937
Entity Emerging Growth Company	false
Entity File Number	0-11634
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3797439
Entity Address, Address Line One	25651 Atlantic Ocean Drive
Entity Address, City or Town	Lake Forest
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92630
City Area Code	626
Local Phone Number	303-7902
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of each class	Common
Trading Symbol(s)	STAA
Name of each exchange on which registered	NASDAQ